#151220

Anti-PDECGF [PGF 44C]

Cat. #151220

Anti-PDECGF [PGF 44C]

Cat. #: 151220

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Platelet-derived endothelial cell growth factor (thymidine phosphorylase); PD-ECGF.

Class: Monoclonal

Application: IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Roy Bicknell

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-PDECGF [PGF 44C]
  • Clone: PGF 44C
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 55 kDa (reduced)
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; IP ; WB
  • Description: PD-ECGF expression is elevated in breast tumours and is a prognostic factor in colon tumours.
  • Immunogen: Full length human protein in E. coli
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1
  • Recommended controls: HUVEC cell or breast carcinoma

Target Details

  • Target: Platelet-derived endothelial cell growth factor (thymidine phosphorylase); PD-ECGF.
  • Molecular weight: 55 kDa (reduced)
  • Tissue cell line specificity: HUVEC cell or breast carcinoma
  • Target background: PD-ECGF expression is elevated in breast tumours and is a prognostic factor in colon tumours.

Applications

  • Application: IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Weng et al. 2012. Basic Clin Pharmacol Toxicol. 110(3):298-306. PMID: 21973306.
  • Enhancement of mitomycin C-induced cytotoxicity by curcumin results from down-regulation of MKK1/2-ERK1/2-mediated thymidine phosphorylase expression.
  • Ko et al. 2011. J Pharmacol Exp Ther. 338(1):184-94. PMID: 21444628.
  • Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
  • Giatromanolaki et al. 2003. J Pathol. 200(2):222-8. PMID: 12754744.
  • DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer.
  • Fox et al. 1997. Ann Oncol. 8(3):271-5. PMID: 9137797.
  • Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
  • Fox et al. 1995. J Pathol. 176(2):183-90. PMID: 7636628.
  • Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.
  • Moghaddam et al. 1995. Proc Natl Acad Sci U S A. 92(4):998-1002. PMID: 7532308.
  • Thymidine phosphorylase is angiogenic and promotes tumor growth.